Oral contraception and the risk of thromboembolism: What does it mean to clinicians and their patients?

Drug Safety

Volumn 25, Issue 13, 2002, Pages 893-902

  Drife, James ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; MESTRANOL; MESTRANOL PLUS NORETYNODREL; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; STEROID;

ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; DEATH; DEVELOPING COUNTRY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; FEMALE; HUMAN; META ANALYSIS; MORTALITY; OBESITY; ORAL CONTRACEPTION; PHYSICIAN; PILL; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; THROMBOEMBOLISM; UNITED KINGDOM; VEIN;

EID: 0036033874     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225130-00001     Document Type: Review

References (68)

1. Jordan AM. Pulmonary, embolism. Lancet 1961; II: 1146-7
2. Inman WHW, Vessey MP, Westerholm MB, et al. Thromboembolic disease and the steroidal content of oral contraceptives: A report to the Committee on Safety of Drugs. BMJ 1970; 2: 203-9
3. Sensible alerts [editorial]. Lancet 1995; 346: 1569
4. Drife J. The third-generation pill controversy (continued). BMJ 2001; 323: 119-20
5. Weber W. Study on risks of third-generation pill 'kept secret by industry' [news item]. Lancet 2001; 357: 779
6. Brock P. Wyeth responds to news story on oral contraceptives and DVT [letter]. BMJ 2001; 322: 1605
7. Skegg DCG. Pitfalls of pharmacoepidemiology. BMJ 2000; 321: 1171-2
8. Drife JO. The benefits of combined oral contraceptives. Br J Obstet Gynaecol 1989; 96: 1225-8
9. Drife JO. The Benefits and Risks of Oral Contraceptives Today. Carnforth: Parthenon, 1996
10. Edwards JE, Oldman A, Smith L, et al. Women's knowledge of, and attitudes to, contraceptive effectiveness and adverse health effects. Br J Fam Plann 2000; 26: 73-80
11. McEwan J, Wadsworth J, Johnson AM, et al. Changes in the use of contraceptive methods in England and Wales over two decades: Margaret Bone's surveys and the National Survey of Sexual Attitudes and Lifestyles. Br J Fam Plann 1997; 23: 5-8
12. Ford NJ, Halliday J, Little J. Changes in the sexual lifestyle of young people in Somerset, 1990-1996. Br J Fam Plann 1999; 25: 55-8
13. Donovan B. Never underestimate the force of reproduction. BMJ 2000; 321: 461-2
14. Office for National Statistics. Abortion Statistics: Legal Abortions Carried Out Under the 1967 Abortion Act in England and Wales, 1999. London: The Stationery Office, 2000
15. Lebow MA. The pill and the press: Reporting risk. Obstet Gynecol 1999; 93: 453-6
16. Hammond PB. Reporting pill panic: A comparative analysis of media coverage of health scares about oral contraceptives. Br J Fam Plann 1997; 23: 62-6
17. Flett G, Gurney E, McKessock L. et al. Impact of the October 1995 pill scare in Grampian. Br J Fam Plann 1998; 24: 18-20
18. Van Heteren G. Wyeth suppresses research on pill, programme claims [news item]. BMJ 2001; 322: 571
19. Williams D, Kelly A, Carvalho M, et al. Effect of the British warning on contraceptive use in the General Medical Service in Ireland. Ir Med J 1998; 91: 202-3
20. Pike MC, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: Possible modifying effect of formulation and age at use. Lancet 1983; 11: 926-30
21. Drife JO. Which pill? BMJ 1983; 287: 1397-9
22. Swyer GIM. Oral contraceptives and cancer [letter]. Lancet 1983; 11: 1019
23. Thorogood M, Vessey MP. Trends in use of oral contraceptives in Britain. Br J Fam Plann 1990; 16: 41-53
24. Gerstman BB, Gross TP, Kennedy DL, et al. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 1991; 81: 90-6
25. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): A randomized clinical trial. Contraception 2000; 61: 295-302
26. Vessey MP, Lawless M. The Oxford-Family Planning Association contraceptive study. Clin Obstet Gynaecol 1984; 11: 743-57
27. Kay CR. The Royal College of General Practitioners' oral contraception study: Some recent observations. Clin Obstet Gynecol 1984; 11: 759-86
28. Ramcharan S, Pellegrin FA, Ray R, et al. The Walnut Creek contraceptive drug study: A prospective study of the side effects of oral contraceptives. Vol. III: An interim report. A comparison of disease occurrence leading to hospitalisation or death in users and nonusers of oral contraceptives. J Reprod Med 1980; 25: 345-72
29. Thorogood M. Oral contraceptives and cardiovascular disease: An epidemiologic overview. Pharmacoepidemiol Drug Saf 1993; 2: 3-16
30. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: Results of the MICA case-control study. BMJ 1999; 318: 1579-83
31. Gillum LA, Mamipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284: 72-8
32. Poulter NR, Chang CL, Farley TMM, et al. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. Lancet 1999; 354: 301-3
33. Gillmer MDG. Metabolic effects of combined oral contraceptives. In: Filshie M, Guillebaud J, editors. Contraception: Science and practice. London: Butterworth, 1989: 11-38
34. Hawkins DF, Elder MG. Human Fertility Control: Theory and Practice. London: Butterworth, 1979
35. London RS. The new era in oral contraception: Pills containing gestodene, norgestimate and desogestrel. Obstet Gynecol Surv 1992; 47: 777-82
36. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994; 49: 1-32
37. MacRae K, Kay C. Third generation oral contraceptive pills [editorial]. BMJ 1995; 311: 1112
38. WHO Collaborative Study. Cardiovascular disease and use of oral contraceptives. Bull World Health Organ 1989; 67: 417-23
39. Drife J. Complications of oral contraception. In: Filshie M, Guillebaud J, editors. Contraception: Science and Practice. London: Butterworth, 1989: 39-51
40. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7
41. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995; 346: 1575-82
42. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
43. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995 Dec 16; 346: 1589-93
44. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. BMJ 1996; 312: 83-8
45. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6
46. Guillebaud J. Advising women on which pill to take. BMJ 1995; 311: 1111-2
47. Weiss N. Third-generation oral contraceptives: How risky? [commentary]. Lancet 1995; 346: 1570
48. Rawlins M. Combined oral contraceptives and thromboembolism [letter]. BMJ 1995; 311: 1232
49. Farmer RDT, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: Analysis of General Practice Research Database. BMJ 2000; 321: 477-9
50. Smith R. Editorial footnote. BMJ 2000; 321: 1172
51. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35
52. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ 2001; 323: 131-4
53. Skegg DCG. Third generation oral contraceptives. BMJ 2000; 321: 190-1
54. Poulter NR. Risk of fatal pulmonary embolism with oral contraceptives [commentary]. Lancet 2000; 355: 2088
55. Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists. First prescription of combined oral contraception: Recommendations for clinical practice. Br J Fam Plann 2000; 26: 27-38
56. Mayor S. Department of Health changes advice on third generation pills [news item]. BMJ 1999; 318: 1026
57. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001
58. Parkin L, Skegg DCG, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 2133-4
59. Lewis G, editor. Why Mothers Die 1997-99. Fifth Report of the Confidential Enquiries into Maternal Deaths in the UK. London: RCOG Press, 2001
60. Hannaford P. Science is not a dispassionate activity [letter]. BMJ 2000; 320: 382
61. Seligsohn U, Lubetsky A, Thrombophilia. N Engl J Med 2001; 345: 697-9
62. Grody WW, Griffin JH, Taylor AK, et al. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3: 139-48
63. Cosmi B, Legnani C, Bernardi F, et al. Value of family history, in identifying women at risk of venous thromboembolism during oral contraception: Observational study. BMJ 2001; 322: 1024-5
64. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31
65. Caplin N, Edelman L. Thrombophilia. N Engl J Med 2001; 345: 697-9
66. World Bank. Safe Motherhood and the World Bank. Lessons from 10 Years of Experience. Washington DC: World Bank, 1999
67. Potts DM, Crane SF. Contraceptive delivery in the developing world. Br Med Bull 1993; 49: 27-39
68. Grubb GS. Women's perceptions of the safety of the pill: A survey in eight developing countries. J Biosoc Sci 1987; 19: 313-21